Blog

Personalized antibody therapies bring precision to treatment. Biointron highlights how monoclonal antibodies and ADCs target cancer, IBD, and other diseases with improved outcomes.

Monoclonal antibodies fight antimicrobial resistance by targeting pathogens and complementing antibiotics. Learn how they expand the arsenal against AMR threats.

Deep learning brings structural modeling of antibodies to new heights. Explore where it succeeds, where it fails, and hybrid strategies that deliver reliable outcomes.

Explore how computational predictors like SCM, TAP, and AlphaFold support therapeutic antibody development through AI-driven workflows and in silico tools.

Harnessing big data in antibody engineering means smarter designs. Explore key databases, their contents, and how to use them to benchmark, compare, and innovate.

Structure modeling platforms from AlphaFold to Rosetta guide smarter antibody design. Learn strengths, caveats, and how to pair predictions with experimental validation.

Deep learning models are redefining antibody research. See how architectures and datasets translate into real-world gains in discovery, screening, and optimization.

AI and computational methods accelerate antibody discovery. Discover how algorithms cut wet-lab cycles, predict properties, and expand the reach of modern biotech.

Antibody labeling matters. Compare conjugation chemistries, optimize labeling degree, and master QC checks that ensure bright, specific, and reproducible results.

Explore how epigenetic antibodies target DNA methylation, histone PTMs, and non-coding RNAs to support gene regulation research using ChIP, ELISA, and other molecular assays.

PepTalk 2024 delivered key insights into antibody development. Explore highlights on formulation, analytics, and modalities that shape the future of biotech innovation.

Cell signaling maps how life communicates. Explore pathways, cross-talk, and the antibody tools that reveal mechanisms behind immunity, cancer, and therapy.